COVID-19 Outcomes, Patient Vaccination Status, and Cancer-Related Delays during the Omicron Wave: A Brief Report from the TERAVOLT Analysis.

Details

Serval ID
serval:BIB_EBBB31952F9C
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
COVID-19 Outcomes, Patient Vaccination Status, and Cancer-Related Delays during the Omicron Wave: A Brief Report from the TERAVOLT Analysis.
Journal
JTO clinical and research reports
Author(s)
Bestvina C.M., Whisenant J.G., Torri V., Cortellini A., Wakelee H., Peters S., Roca E., De Toma A., Hirsch F.R., Mamdani H., Halmos B., Arrieta O., Metivier A.C., Fidler M.J., Rogado J., Presley C.J., Mascaux C., Genova C., Blaquier J.B., Addeo A., Finocchiaro G., Khan H., Mazieres J., Morgillo F., Bar J., Aujayeb A., Mountzios G., Scotti V., Grosso F., Geraedts E., Zhumagaliyeva A.N., Horn L., Garassino M.C., Baena J.
Working group(s)
TERAVOLT study group
ISSN
2666-3643 (Electronic)
ISSN-L
2666-3643
Publication state
Published
Issued date
20/05/2022
Peer-reviewed
Oui
Pages
100335
Language
english
Notes
Publication types: Journal Article
Publication Status: aheadofprint
Abstract
The Thoracic Centers International COVID-19 Collaboration (TERAVOLT) registry found ∼ 30% mortality in patients with thoracic malignancies during the initial COVID surges. Data from South Africa suggested a decrease in severity and mortality with the Omicron wave. Our objective was to assess mortality of patients with thoracic malignancies with the Omicron-predominant wave, and efficacy of vaccination.
A prospective, multicenter observational study was conducted. Twenty-eight institutions contributed data from January 14, 2022 through February 4, 2022. Inclusion criteria was any thoracic cancer and a COVID-19 diagnosis on or after November 1, 2021. Endpoints included mortality, hospitalization, symptomatic COVID infection, asymptomatic COVID infection, and delay in cancer therapy. Analysis was done through contingency tables and a multivariable logistic model.
We enrolled 346 patients. Median age was 65, 52.3% were female, 74.2% were current or former smokers, 86% had NSCLC, 72% were Stage IV at time of COVID diagnosis, and 66% were receiving therapy. Variant was unknown for 70%; for those known, Omicron represented 82%. Overall mortality was 3.2%. Using multivariate analysis, COVID vaccination with booster compared with no vaccination showed a protective effect on hospitalization or death (OR 0.30, CI 0.15-0.57, p=0.0003), while vaccination without booster did not (OR of 0.64, CI 0.33-1.24, p=0.1864). Cancer care was delayed in 56.4% of patients.
TERAVOLT found reduced patient mortality with the most recent COVID surge. COVID vaccination with booster improved outcomes of hospitalization or death. Delays in cancer therapy remain an issue, which has the potential to worsen cancer-related mortality.
Pubmed
Open Access
Yes
Create date
17/06/2022 13:14
Last modification date
11/11/2022 6:39
Usage data